Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relative Bioavailability of Apalutamide in Applesauce vs Whole Tablets
NCT03802682Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jan 2019
- Primary completion
- Apr 2019
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of apalutamide in prostate cancer (PCa) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Maximum Plasma Concentration, Area Under the Plasma Concentration-time Curve From Time 0 to 72 hours and 1 more. Started Jan 2019; status: completed.
02
Drugs
apalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT03802682.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03802682.